MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns, the peer-reviewed Journal of the ...

NexoBrid ® is a topically administered biological orphan drug that enzymatically removes eschar while preserving viable ...

In addition, the MediWound management team will host one-on-one meetings during the conference. Interested investors are encouraged to contact their TD Cowen representative to schedule a meeting.

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

MediWound's first drug, NexoBrid ®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for ...

Background: This study aimed to analyze the clinical course of a newborn with congenital scrub typhus caused by vertical transmission and explore early diagnosis and treatment strategies. The clinical ...